However, It is also worth mentioning that HDAC inhibitors are currently being studied in ALS associated with FUS or TARDBP-43 mutations, so it is not clear whether this therapy would also be effective in sporadic ALS cases. Here, FUS is linked to amyotrophic lateral sclerosis.